Cancer test clearance
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Veridex gains 510(k) clearance for use of its CellSearch test system as an aid in monitoring metastatic colorectal cancer. The system, which counts circulating tumor cells, is already cleared to help monitor metastatic beast cancer. The CellSearch test reagents are supplied by Immunicon, but that company is seeking to terminate the exclusive marketing agreement it has with Veridex (1"The Gray Sheet" June 11, 2007, p. 10)
You may also be interested in...
CellSearch for prostate cancer
FDA clears metastatic prostate cancer indication for Johnson & Johnson/Veridex's CellSearch circulating tumor cell test system, Veridex announces Feb. 27. The clearance was based on a 65-center, 231-patient study which showed that circulating tumor cells are a strong independent predictor of progression-free survival and overall survival. CellSearch is already cleared to aid in monitoring metastatic breast and colorectal cancers (1"The Gray Sheet" Nov. 26, 2007, In Brief)
J&J-Immunicon Dispute Highlights Challenges Of Exclusive Agreements
A sales and marketing relationship gone sour between cancer diagnostic developer Immunicon and a Johnson & Johnson subsidiary illustrates the risks firms take when choosing an exclusive distributor
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.